

Special Issue

Viral Hepatitis: From Pathophysiology to Therapeutic Approaches

Message from the Guest Editor

Viral hepatitis remains a leading global cause of liver disease, cancer, and mortality, despite major advances in prevention and treatment. This Special Issue aims to bring together current research and emerging insights that deepen our understanding of viral pathogenesis and host–virus interactions, while highlighting new diagnostic, therapeutic, and preventive strategies. We invite contributions focusing on all major hepatotropic viruses, including HBV, HCV, HDV, and HEV, as well as relevant model systems and comparative studies.

Topics of interest include mechanisms of viral persistence, immune evasion, and liver injury; development of antiviral resistance; host genetic and immunologic determinants of disease outcome; and advances in vaccines, antiviral agents, and immunomodulatory therapies. We also welcome translational and clinical studies exploring biomarkers, treatment optimization, and viral co-infections in special populations. By integrating mechanistic, translational, and clinical perspectives, this collection seeks to inform future strategies for achieving global hepatitis elimination and improving patient care.

Guest Editor

Dr. Manish C. Choudhary

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/259344

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).